Novelion Therapeutics (NVLN) was quite active in trading today. The stock has been mostly bullish since Thursday morning after the company confirmed that it had secured funding to continue its operations into 2019. The company has products already approved by the FDA and has six other products in development either at phase 2 or phase 3 status. However, NVLN has a relatively high amount of debt and thus news of its securing funding set the stock into motion. Here’s a recap of what’s happened to NVLN over the last two days.